Join the Renal Cell Carcinoma group to help and get support from people like you.
Renal Cell Carcinoma News
Related terms: Adenocarcinoma of renal cells, Cancer, Hypernephroma, Cancer, Kidney, Cancer, Renal, Cancer, Renal Cell Carcinoma, Hypernephroma, Kidney Cancer, Renal Cancer
GWAS Identifies 108 Independent Risk Loci for Kidney Cancer
THURSDAY, May 2, 2024 – A genome-wide association study meta-analysis, published online April 26 in Nature Genetics, has identified 63 susceptibility regions containing 108 independent risk loci for...
Improvement Seen in Survival With Adjuvant Pembrolizumab in Kidney Cancer
THURSDAY, April 18, 2024 – For patients with clear-cell renal cell carcinoma, adjuvant pembrolizumab is associated with a significant and clinically meaningful improvement in overall survival,...
Pembrolizumab Shows Survival Benefit for Patients With Renal Cancer
WEDNESDAY, Jan. 31, 2024 – For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of...
Injected Opdivo for Kidney Cancer Works Equally Well as IV Form: Study
TUESDAY, Jan. 30, 2024 – Opdivo, one of the new generation of immunotherapy cancer treatments, appears to help kidney cancer patients equally well when given as a quick injection versus the current...
FDA Approves Merck’s Welireg (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
RAHWAY, N.J.--(BUSINESS WIRE) December 14, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
Survival Improved With Everolimus in High-Risk Clear Cell Renal Cancer
MONDAY, Oct. 23, 2023 – For patients with clear cell renal cell carcinoma (RCC) at very high risk for recurrence, adjuvant everolimus is associated with significantly improved recurrence-free...
Higher Cardiorespiratory Fitness Protects Men Against Many Cancers
THURSDAY, Aug. 17, 2023 – Higher cardiorespiratory fitness protects men against many site-specific cancers, according to a study published online Aug. 15 in the British Journal of Sports Medicine....
Could Ativan Pose Harm to People Battling Pancreatic Cancer?
THURSDAY, Aug. 17, 2023 – Sometimes patients with pancreatic cancer are prescribed the benzodiazepine lorazepam (Ativan) for anxiety, but that may be harming their health. A new study found this...
Fit When Young? You May Have a Lower Risk of 9 Cancers as You Age
WEDNESDAY, Aug. 16, 2023 – Having good fitness while young can really pay off when it comes to cancer risk later in life. New research found that cardiorespiratory fitness – the ability to do...
Younger Kidney Cancer Patients on VEGF Inhibitors at Elevated Risk for Hypertension
WEDNESDAY, July 26, 2023 – Hypertension during treatment is common among adolescents and young adults (AYAs) being treated with vascular endothelial growth factor (VEGF) inhibitors for renal cancer,...
ASCO: Adding Atezolizumab to Cabozantinib No Benefit in Advanced Renal Cancer
FRIDAY, June 9, 2023 – For patients with locally advanced or metastatic renal cell carcinoma with disease progression on or after immune checkpoint inhibitor treatment, the addition of atezolizumab...
FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin
Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option ...
FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin
BRIDGEWATER, N.J.--(BUSINESS WIRE) April 13, 2022 --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
August 11, 2021 Keytruda Plus Lenvima Is Now Approved for Two Types of Cancer, Including Advanced RCC Based on Phase 3 CLEAR/KEYNOTE-581 Trial, Keytruda Plus Lenvima Significantly Reduced Risk of...
FDA Approves Fotivda (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma
BOSTON--(BUSINESS WIRE) March 10, 2021 – AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved Fotivda (tivozanib) for the treatment of adults...
Ask a question
To post your own question to this support group, sign in or create an account.